Yazar "Gurel, Ayse" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Caffeic Acid Phenethyl Ester (CAPE) inhibits growth of head and neck squamous cancer stem cells(Canadian Soc Clinical Investigation, 2015) Ciftci-Yilmaz, Sultan; Yilmaz, Sultan; Gurel, Ayse; Ocal, Fikret Emre; Keles, Alican; Barut, Ahmet Emre; Isik, BulentPurpose: Cancer stem cells are resistant to chemotherapy and radiotherapy and are implicated in tumor relapse and high patient mortality. Substances impairing cancer stem cell activity could be very useful as novel cancer therapeutics. Caffeic acid phenethyl ester (CAPE), a component of propolis, whose antitumor activity has been confirmed in several tumor types in vitro, has recently been shown to inhibit the growth of some cancer stem cell types. Methods: An ALDH1-positive fraction was isolated from UT-SCC-74A cells as cancer stem cells by magnetic-activated cell sorting. The isolated cells were characterized by sphere formation assay and biomarkers of cancer stem cells were analyzed by quantitative RT-PCR. To demonstrate the effect of CAPE on head and neck squamous cancer stem cells, XTT cell viability assays were performed. Results: Increasing concentrations of CAPE decrease the viability of head and neck squamous cancer stem cells. IC50 value was calculated from XTT results as 50.29 mu g/ml. Conclusion: CAPE has a growth inhibitory effect on head and neck squamous cancer stem cells in vitro.Öğe Caffeic Acid Phenethyl Ester: Its Protective Role Against Certain Major Eye Diseases(Mary Ann Liebert, Inc, 2014) Akyol, Sumeyya; Ugurcu, Veli; Balci, Mehmet; Gurel, Ayse; Erden, Gonul; Cakmak, Ozlem; Akyol, OmerAs an effective compound found mainly in the honeybee product propolis, caffeic acid phenethyl ester (CAPE) has been commonly utilized as a medicine and remedial agent, in a number of countries. Specifically, it might inhibit nuclear factor kappa B at micromolar concentrations and demonstrate antioxidant, antineoplastic, antiproliferative, cytostatic, antiviral, antibacterial, antifungal, and anti-inflammatory features. This review article summarizes the recent progress regarding the favorable effects of CAPE on a number of eye disease models, including cataract and posterior capsule opacification, corneal diseases, retina and optic nerve-related diseases, ischemia/reperfusion injury of retina, inflammation and infection-related diseases. CAPE has been found to exhibit promising efficacy, with minimal adverse effects, in animal and cell culture studies of several eye diseases.Öğe Effects of Ginkgo biloba extract on brain oxidative condition after cisplatin exposure(Canadian Soc Clinical Investigation, 2016) Aydin, Duygu; Peker, Emine G. G.; Karakurt, Meryem D.; Gurel, Ayse; Ayyildiz, Mustafa; Cevher, Sule C.; Agar, ErdalPurpose: The purpose of this study was to evaluate the efficacy of Ginkgo biloba extract (EGb 761) on oxidative events of brain in cisplatin-administrated rats. Methods: Rats were divided into four experimental groups: 1) control (n=6); 2) cisplatin (8 mg/kg, intraperitoneally one dose, n=6); 3) EGb 761 (100 mg/kg intraperitoneally for 15 days, n=6); and 4) cisplatin + EGb 761 (n=6). After drug administration, rats were sacrificed and brain tissues were removed. Nitric oxide (NO), malondialdehyde (MDA) and glutathione (GSH) levels were evaluated in brain tissues. Results: Single dose cisplatin administration significantly increased NO and GSH levels, but decreased MDA levels in brain tissue samples. EGb 761 treatment reversed the effects of cisplatin on NO and GSH levels, but did not affect the decreased MDA levels. Conclusion: Results of the study indicate that oxidative stress can be an important pathogenetic mechanism of cisplatin-induced neurotoxicity. EGb 761, an standardized extract of G. biloba leaves that has antioxidant properties, may improve the oxidative stress-related neurological side effects of cisplatin.Öğe Effects of pretreatment with esmolol and lidocaine on injection pain and rocuronium-induced withdrawal response(Tubitak Scientific & Technological Research Council Turkey, 2015) Ergil, Julide; Kavak Akelma, Fatma; Ozkan, Derya; Bumin Aydin, Gozde; Gurel, Ayse; Akinci, MelihBackground/aim: We aimed to compare the effectiveness of esmolol 1 mg/kg and lidocaine 1 mg/kg for injection pain and for the prevention of rocuronium-induced withdrawal response. Materials and methods: We enrolled a total of 81 patients in the study. Patients were randomly assigned to receive either 10 mL of 0.9% NaCl (Group P), esmolol 1 mg/kg (Group E), or lidocaine 1.0 mg/kg (Group L). A subparalyzing dose of rocuronium 0.05 mg/kg was administered to all patients and its effects were recorded. Anesthesia was induced with intravenous propofol and intravenous rocuronium 0.5 mg/kg in all groups. The withdrawal movements of the patient groups were subsequently graded. Results: There was a statistically significant difference in overall incidence of pain in group E and L compared to the placebo group after administrating the subparalyzed dose (no pain response: Group E = 81.5%, Group L = 77.8%, Group P = 14.8%) (P < 0.001). After intravenous administration of an intubating dose of rocuronium, the esmolol group had a significantly lower incidence of withdrawal movement than the other groups (no response: Group E = 81.5%, Group L = 63%, Group P = 22.2%) (P < 0.001). Conclusion: We found that esmolol significantly attenuates rocuronium-induced withdrawal movement and also reduces pain when used at subparalyzing doses.
